THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Kelly Standifer to Narcotic Antagonists

This is a "connection" page, showing publications Kelly Standifer has written about Narcotic Antagonists.
Connection Strength

1.215
  1. Post-blast treatment with Nociceptin/Orphanin FQ peptide (NOP) receptor antagonist reduces brain injury-induced hypoxia and signaling proteins in vestibulomotor-related brain regions. Behav Brain Res. 2018 03 15; 340:183-194.
    View in: PubMed
    Score: 0.541
  2. Nociceptin/orphanin FQ peptide receptor antagonist JTC-801 reverses pain and anxiety symptoms in a rat model of post-traumatic stress disorder. Br J Pharmacol. 2015 Jan; 172(2):571-82.
    View in: PubMed
    Score: 0.460
  3. beta-Funaltrexamine inactivates ORL1 receptors in BE(2)-C human neuroblastoma cells. Eur J Pharmacol. 2000 Aug 18; 402(1-2):R1-37.
    View in: PubMed
    Score: 0.176
  4. Reduction by central beta-funaltrexamine of food intake in rats under freely-feeding, deprivation and glucoprivic conditions. Brain Res. 1990 Dec 03; 535(1):101-9.
    View in: PubMed
    Score: 0.022
  5. Differential blockade of morphine and morphine-6 beta-glucuronide analgesia by antisense oligodeoxynucleotides directed against MOR-1 and G-protein alpha subunits in rats. Neurosci Lett. 1995 Sep 29; 198(2):99-102.
    View in: PubMed
    Score: 0.008
  6. TIPP[psi], a highly selective delta ligand. Neurosci Lett. 1994 Nov 07; 181(1-2):47-9.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES